$1.27-0.03 (-2.31%)
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
MediciNova, Inc. in the Healthcare sector is trading at $1.27. Wall Street consensus targets $9.00 (3 analysts), implying a +608.7% move over the next 12 months. The stock is currently near its 52-week low of $1.17, remaining 9.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory ...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Friday reported a loss of $2.8 million in its fourth quarter.
As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by...
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Wednesday reported a loss of $3.1 million in its third quarter.